TITLE

Tipranavir cost effective in treatment-experienced HIV

PUB. DATE
July 2006
SOURCE
PharmacoEconomics & Outcomes News;7/15/2006, Issue 507, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses research being done on the cost effectiveness of tipranavir for treatment-experienced patients with HIV infections. Reference to a study by K. N. Simpson et al, published in the May to June 2006 issue of "Value in Health"; Range of the incremental cost-effectiveness ratio for ritonavir-boosted tipranavir; Safety and efficacy of ritonavir-boosted tipranavir.
ACCESSION #
21778992

 

Related Articles

  • Addition of enfuvirtide: is it worth it in advanced HIV?  // PharmacoEconomics & Outcomes News;7/2/2005, Issue 481, p10 

    Presents the results of a study on the effectiveness of enfuvirtide treatment in patients with HIV infection. Projected quality-adjusted life expectancy (QALY) for patients who received optimized therapy; Cost effectiveness of enfuvirtide plus optimized therapy per QALY.

  • A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals. Kühne, Felicitas C.; Chancellor, Jeremy; Mollon, Patrick; Myers, Daniela E.; Louie, Michael; Powderly, William G. // HIV Clinical Trials;Mar/Apr2010, Vol. 11 Issue 2, p80 

    Purpose: Maraviroc (MVC) is the first approved CCR5 antagonist. The aim of this study was to explore the cost-effectiveness of MVC in treatment-experienced or treatment-resistant HIV-infected adults.Methods: The validated HIV microsimulation model ARAMIS was used to predict clinical and economic...

  • treatment-naïve:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p216 

    A definition of the term "treatment-naïve" is presented. It refers to patients who have no history of having been treated for a specific condition with a particular drug. HIV-positive persons who have not been subjected to monotherapy have the best chance of driving their viral load to...

  • HIV treatments -- the state of play. Maynard, Tony // HIV Australia;Jun-Aug2004, Vol. 3 Issue 4, p20 

    Traces the progress of HIV medication in Australia. Conditions of people living with HIV/AIDS diseases; Situations that call for the treatment of the disease; Classes of drugs formulated for the disease; Factors that contributed to the success of HIV medication.

  • "Significant cost savings" accrued with discontinuation of HAART.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p9 

    Discusses research being done on cost saving and clinical outcome associated with the discontinuation of therapy in HIV patients. Reference to a study by P. Keiser and colleagues, presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment in July 2005;...

  • Cross Regulation of Sirtuin 1, AMPK, and PPARγ in Conjugated Linoleic Acid Treated Adipocytes. Shan Jiang; Wei Wang; Miner, Jess; Fromm, Michael // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) reduces triglyceride (TG) levels in adipocytes through multiple pathways, with AMP-activated protein kinase (AMPK) generally facilitating, and peroxisome proliferator-activated receptor γ (PPARγ) generally opposing these reductions....

  • Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings. Meya, David B.; Manabe, Yukari C.; Castelnuovo, Barbara; Cook, Bethany A.; Elbireer, Ali M.; Kambugu, Andrew; Kamya, Moses R.; Bohjanen, Paul R.; Boulware, David R. // Clinical Infectious Diseases;8/15/2010, Vol. 51 Issue 4, p448 

    Background. Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART).We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify...

  • The Cost-Effectiveness of Monitoring Strategies for Antiretroviral Therapy of HIV Infected Patients in Resource-Limited Settings: Software Tool. Estill, Janne; Salazar-Vizcaya, Luisa; Blaser, Nello; Egger, Matthias; Keiser, Olivia // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: The cost-effectiveness of routine viral load (VL) monitoring of HIV-infected patients on antiretroviral therapy (ART) depends on various factors that differ between settings and across time. Low-cost point-of-care (POC) tests for VL are in development and may make routine VL...

  • The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Ross, Eric L.; Weinstein, Milton C.; Schackman, Bruce R.; Sax, Paul E.; Paltiel, A. David; Walensky, Rochelle P.; Freedberg, Kenneth A.; Losina, Elena // Clinical Infectious Diseases;Apr2015, Vol. 60 Issue 7, p1102 

    Background. Long-acting antiretroviral therapy (LA-ART) is currently under development and could improve outcomes for human immunodeficiency virus (HIV)-infected individuals with poor daily ART adherence. Methods. We used a computer simulation model to evaluate the cost-effectiveness of 3 LA-ART...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics